Status | Study |
Recruiting |
Study Name: Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3) Condition: Neuroendocrine Carcinoma Date: 2014-07-24 Interventions: Drug: Everolimus , temozolomide |
Active, not recruiting |
Study Name: 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial Condition: Neuroendocrine Carcinoma of the Lung and Thymus Date: 2012-03-20 Interventions: Drug: Pasireotide LAR 60 mg i. |
Completed |
Study Name: Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma Condition: Neuroendocrine Carcinoma Date: 2008-04-18 Interventions: Drug: Atiprimod Oral, 14 days on / 14 days off; 30mg capsules |
Completed |
Study Name: Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma Condition: Neuroendocrine Carcinoma Date: 2008-01-22 Interventions: Drug: Avastin 15 mg/kg By Vein |
Completed |
Study Name: Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma Condition: Neuroendocrine Carcinoma Date: 2006-10-11 Interventions: Drug: Atiprimod oral, 14 days on / 14 days off; 30mg capsules |
Completed |
Study Name: Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract Condition: Gastrointestinal Cancer Carcinoma, Neuroendocrine Date: 2006-07-13 Interventions: Drug: Cisplatin Cisplatin 25 m |
Completed |
Study Name: Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma Condition: Neuroendocrine Carcinoma Date: 2005-09-12 Interventions: Drug: Paclitaxel Drug: Carboplatin |
Completed |
Study Name: RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma Condition: Neuroendocrine Carcinoma Islet Cell Carcinoma Date: 2005-06-07 Interventions: Drug: RAD001 Starting dose of |
Completed |
Study Name: S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer Condition: Neuroendocrine Carcinoma of the Skin Date: 1999-11-01 Interventions: Drug: CMF regimen Drug: cyclophosphamide |
Not yet recruiting |
Study Name: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas Condition: Date: 2024-05-05 |